LGBTQ Nation on MSN
U.S. ships groundbreaking HIV drug to Africa, but slashed funding threatens progress
The U.S. just shipped two million doses of lenacapavir, a groundbreaking twice-a-year HIV-prevention injectable medication, ...
Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...
Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval ...
To mark World AIDS Day, the Institute for Contemporary Arts will screen our film tackling the collapse of USAID funding ...
Data from a new surveillance report show rising resistance to ceftriaxone and cefixime, the two antibiotics currently ...
Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...
Novo Nordisk is expected to announce soon whether its blockbuster GLP-1 drug semaglutide can help slow Alzheimer’s disease ...
The drug lenacapavir will be distributed to Eswatini and Zambia — the first step toward providing at least 2 million doses to ...
The United States said Tuesday it has delivered a new treatment to prevent HIV in two African countries, months after President Donald Trump dramatically cut global aid.
Eswatini has become the first African country to receive lenacapavir, a twice-yearly HIV prevention injection that global ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the delivery of first shipments of lenacapavir – Gilead’s twice-yearly ...
For gangs, the Misuse of Drugs Act (1975) has been one of the best recruiting tools they’ve ever had. Criminalisation of a raft of illicit drugs not only provide s them with a wildly lucrative black ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback